In phase III: Semaglutide 2.4 mg (STEP-1): nausea 44.2%, diarrhea 31.5%, vomiting 24.8% Tirzepatide 15 mg (SURMOUNT-1): nausea 29.2%, diarrhea 23.0%, constipation 16.8% Retatrutide 12 mg (TRIUMPH-1): nausea 37.2%, vomiting 22.0%, diarrhea 27.1% Key observation: tirzepatide shows the most favorable GI profile at equivalent dose, likely tied to the GIP component dampening GLP-1-mediated nausea signaling at the brainstem level
Hashimoto's thyroiditis is the most common cause of hypothyroidism in the UK and represents an autoimmune condition where the immune system mistakenly attacks the thyroid gland
The HMONs-MnPpIX-PEG system was quickly broken down by GSH, which enhanced the therapeutic efficiency of sonodynamic treatment
Future Directions, Current Limitations, and Emerging Areas for Research In conclusion, the collective clinical and preclinical evidence robustly supports the potential of GLP-1RAs as a promising therapeutic strategy for obesity-related asthma and/or low T2 asthma
Thiamine is especially important for alcohol and drug detox, because chronic alcohol use causes thiamine deficiency, which leads to Wernickes encephalopathy and Korsakoff syndrome, as studied by Martin PR, Singleton CK, Hiller-Sturmhfel S
10.1016/S0006-8993(99)01964-2 259